RS60795B1 - Vezujući molekuli specifični za il-21 i njihove upotrebe - Google Patents

Vezujući molekuli specifični za il-21 i njihove upotrebe

Info

Publication number
RS60795B1
RS60795B1 RS20201046A RSP20201046A RS60795B1 RS 60795 B1 RS60795 B1 RS 60795B1 RS 20201046 A RS20201046 A RS 20201046A RS P20201046 A RSP20201046 A RS P20201046A RS 60795 B1 RS60795 B1 RS 60795B1
Authority
RS
Serbia
Prior art keywords
binding molecules
molecules specific
specific
binding
molecules
Prior art date
Application number
RS20201046A
Other languages
English (en)
Inventor
Catherine Ettinger
Jodi Karnell
Melissa Damschroder
Partha Chowdhury
Xiaodong Xiao
Ping Tsui
Reena Varkey
Stacey Drabic
Laura Carter
Ronald Herbst
Qun Du
Brian Michael Naiman
Original Assignee
Boston Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60795(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boston Pharmaceuticals Inc filed Critical Boston Pharmaceuticals Inc
Publication of RS60795B1 publication Critical patent/RS60795B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
RS20201046A 2014-04-08 2015-04-07 Vezujući molekuli specifični za il-21 i njihove upotrebe RS60795B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976684P 2014-04-08 2014-04-08
PCT/US2015/024650 WO2015157238A2 (en) 2014-04-08 2015-04-07 Binding molecules specific for il-21 and uses thereof
EP15776002.6A EP3128997B1 (en) 2014-04-08 2015-04-07 Binding molecules specific for il-21 and uses thereof

Publications (1)

Publication Number Publication Date
RS60795B1 true RS60795B1 (sr) 2020-10-30

Family

ID=54288526

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20201046A RS60795B1 (sr) 2014-04-08 2015-04-07 Vezujući molekuli specifični za il-21 i njihove upotrebe

Country Status (23)

Country Link
US (4) US10022443B2 (sr)
EP (2) EP3128997B1 (sr)
KR (1) KR102546611B1 (sr)
CN (2) CN111560071B (sr)
AU (2) AU2015244025B2 (sr)
CA (2) CA2948275C (sr)
CY (1) CY1123275T1 (sr)
DK (1) DK3128997T3 (sr)
ES (1) ES2814150T3 (sr)
HR (1) HRP20201377T1 (sr)
HU (1) HUE051676T2 (sr)
IL (2) IL248709B (sr)
LT (1) LT3128997T (sr)
MA (2) MA50678A (sr)
PL (1) PL3128997T3 (sr)
PT (1) PT3128997T (sr)
RS (1) RS60795B1 (sr)
RU (1) RU2708336C2 (sr)
SG (2) SG11201609178SA (sr)
SI (1) SI3128997T1 (sr)
TW (1) TWI665214B (sr)
WO (1) WO2015157238A2 (sr)
ZA (1) ZA201707489B (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223283A1 (en) 2016-06-22 2017-12-28 Icahn School Of Medicine At Mount Sinai Hcv core and minicore binding molecules
AU2017394032B8 (en) 2017-01-21 2020-10-22 Guangzhou Hanfang Pharmaceutical Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
CN109503715B (zh) * 2017-09-15 2023-12-15 科济生物医药（上海）有限公司 Il-4r的融合蛋白及其应用
CR20200330A (es) 2018-01-12 2020-12-23 Amgen Inc Anticuerpos anti-pd-1 y métodos de tratamiento
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113321729B (zh) * 2021-07-01 2022-08-30 东大生物技术(苏州)有限公司 一组il-12单克隆抗体及其医药用途
CN116554323B (zh) * 2023-04-27 2024-02-27 中南大学湘雅二医院 人源化抗il21抗体的开发和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3546807C2 (sr) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
PL358215A1 (en) 2000-03-24 2004-08-09 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US20070092485A1 (en) 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
CA2566745A1 (en) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
BRPI0514138A (pt) 2004-08-05 2008-05-27 Wyeth Corp método para tratar, melhorar, ou prevenir um distúrbio, proteìna de fusão, vetor, célula hospedeira recombinante, método para produzir uma proteìna de fusão, composição farmacêutica, e, métodos para transplantar/enxertar um órgão, tecido, célula ou grupo de células em um indivìduo mamìfero, e para tratar, prevenir ou melhorar rejeição de transplante/enxerto em um receptor de transplante/enxerto mamìfero
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
ITRM20040586A1 (it) 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
US7592427B2 (en) 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20080267910A1 (en) 2007-03-09 2008-10-30 Wu Paul W Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
KR101615215B1 (ko) * 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
EP2287174B8 (en) 2008-01-18 2016-12-07 Bio-Rad Laboratories, Inc. Enhanced purification of antibody fragments by apatite chromatography
JP2011517319A (ja) * 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ１２結合タンパク質
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
KR20110025215A (ko) 2008-06-30 2011-03-09 온코세라피 사이언스 가부시키가이샤 방사성 동위원소 표지로 표지된 항―ｃｄｈ３ 항체 및 이의 용도
EP2488867B1 (en) * 2009-10-14 2020-09-30 Janssen Biotech, Inc. Methods of affinity maturing antibodies
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
AU2015244025A1 (en) 2016-11-17
US10588969B2 (en) 2020-03-17
PT3128997T (pt) 2020-09-04
AU2019202447B2 (en) 2020-09-10
US20180318416A1 (en) 2018-11-08
KR20170018814A (ko) 2017-02-20
TW201620934A (zh) 2016-06-16
US20230201346A1 (en) 2023-06-29
CN111560071A (zh) 2020-08-21
CA2948275A1 (en) 2015-10-15
IL248709A0 (en) 2017-03-30
US11529415B2 (en) 2022-12-20
NZ725735A (en) 2023-09-29
AU2015244025B2 (en) 2019-03-21
HUE051676T2 (hu) 2021-03-29
ES2814150T3 (es) 2021-03-26
KR102546611B1 (ko) 2023-06-22
IL248709B (en) 2020-08-31
CY1123275T1 (el) 2021-12-31
ZA201707489B (en) 2019-06-26
US20200164069A1 (en) 2020-05-28
EP3128997A4 (en) 2017-12-13
CN106794129A (zh) 2017-05-31
CN111560071B (zh) 2023-09-05
RU2016143378A3 (sr) 2019-01-21
EP3689325A1 (en) 2020-08-05
WO2015157238A2 (en) 2015-10-15
CN106794129B (zh) 2020-05-12
CA2948275C (en) 2023-10-17
CA3208721A1 (en) 2015-10-15
MA50678A (fr) 2020-08-05
RU2708336C2 (ru) 2019-12-05
WO2015157238A3 (en) 2015-12-10
US10022443B2 (en) 2018-07-17
SI3128997T1 (sl) 2020-11-30
SG11201609178SA (en) 2016-12-29
TWI665214B (zh) 2019-07-11
SG10201913627TA (en) 2020-03-30
LT3128997T (lt) 2020-10-12
RU2016143378A (ru) 2018-05-08
MA39821B1 (fr) 2020-09-30
US20170173149A1 (en) 2017-06-22
IL273641A (en) 2020-05-31
NZ762893A (en) 2023-10-27
IL273641B (en) 2021-04-29
AU2019202447A1 (en) 2019-05-02
MA39821A (fr) 2017-02-15
EP3128997B1 (en) 2020-08-05
HRP20201377T1 (hr) 2021-02-19
DK3128997T3 (da) 2020-08-24
PL3128997T3 (pl) 2020-12-28
EP3128997A2 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
IL251891A0 (en) CD73-specific binding molecules and uses thereof
IL249269A0 (en) Trispecific molecules and methods of using them
IL254223A (en) CD20 binding compounds and their uses
IL273641B (en) Specific binding molecules for il-21 and uses thereof
GB201412659D0 (en) Molecules
GB201412658D0 (en) Molecules
ZA201702173B (en) Sorbent for binding metal and production thereof
GB201612520D0 (en) Binding molecules
SG11201705583XA (en) Cxcr4 binding molecules
EP3102611A4 (en) Humanized beta-amyloid binding molecules and uses thereof
GB201413311D0 (en) Book
IL252932A0 (en) Anti-cxcl12 antibody molecules and their uses
EP3180027A4 (en) Rspo1 binding agents and uses thereof
GB201508729D0 (en) Binding molecules
GB201413567D0 (en) Binding surfaces